Real-world Evidence Study on the Performance and Safety of Halova Ovules

NCT ID: NCT05654610

Last Updated: 2023-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

249 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-01

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open-label, multicentric, non-randomized, single-arm, pilot, interventional clinical investigation to confirm the tolerability and performance of the medical device Halova in lubrication of the vagina and vaginal atrophy treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this investigation is to evaluate the therapeutic performance and tolerability of Halova ovules in treating vaginal atrophy and restoring the natural lubrication of the vaginal mucosa.

The secondary objective of this clinical investigation are to evaluate the performance of the medical device by clinical examination, and the degree of patient satisfaction related to the intended use (Likert scale).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Halova

Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult women, aged between 18 and above, in pre-menopause or menopause;
* Adult women with atrophic vaginitis caused by estrogen hormone deficiency;
* Adult women who have vaginal dryness as a result of contraceptive treatment or other disorders;
* Subjects with a normal cervical cytology report, e.g. Negative for intraepithelial lesions or malignancy (NILM) or slightly changed to atypical squamous cells of undetermined significance (ASC-US) in the last 6 months;
* Subjects willing to provide signed informed consent for participation in clinical investigation.

Exclusion Criteria

* Subjects with vulvar or cervical cancer.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MDX Research

NETWORK

Sponsor Role collaborator

Perfect Care Distribution

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ema Peta

Role: STUDY_DIRECTOR

Perfect Care Distribution

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Spitalul Clinic Dr. Ion Cantacuzino Bucharest

Bucharest, , Romania

Site Status

Med Life Humanitas Cluj-Napoca

Cluj-Napoca, , Romania

Site Status

Cabinet Medical - Dr. Saleh K. Majed

Craiova, , Romania

Site Status

Cabinet Medical - Dr. Surpanelu Oana

Iași, , Romania

Site Status

MediBlue

Iași, , Romania

Site Status

Clinica Natisan Pitesti

Piteşti, , Romania

Site Status

Cabinet Dr. Rădulescu G. Mihaela Elena

Râmnicu Vâlcea, , Romania

Site Status

Ramnicu Valcea

Râmnicu Vâlcea, , Romania

Site Status

Cabinet Ginecologic Dr. Popescu Sibiu

Sibiu, , Romania

Site Status

Clinica iMED

Sibiu, , Romania

Site Status

Pan Medical Sibiu

Sibiu, , Romania

Site Status

Bradmed SRL

Târgu Jiu, , Romania

Site Status

Clinica Medicala Dr. Cioata Ionel Trifon

Timișoara, , Romania

Site Status

Spitalul Judetean de Urgenta Tulcea

Tulcea, , Romania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Romania

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HALOVRW/01/2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women
NCT06197568 NOT_YET_RECRUITING PHASE1/PHASE2
GoldenCareTM for the Treatment of Bacterial Vaginosis
NCT01762670 TERMINATED PHASE1/PHASE2
Regenerative Treatment of Female Genital Atrophy
NCT07306611 COMPLETED PHASE1/PHASE2
Vaginal Preparation Prior to Hysterectomy
NCT03412734 TERMINATED PHASE4